【摘要】：目的:觀察消疹止癢噴劑治療表皮生長因子受體抑制劑(EGFRI)相關(guān)性皮疹的臨床療效及安全性。方法:選擇2015年5月-2016年5月于我院腫瘤科確診為惡性腫瘤、接受EGFRI治療后出現(xiàn)皮疹的患者60例,按患者用藥意愿分成試驗組(40例)和對照組(20例)。對照組患者不采取任何藥物治療皮疹;試驗組患者使用消疹止癢噴劑噴患處,治療頻次由醫(yī)師根據(jù)皮疹分級確定為1級1~2次/d、2級2~3次/d、3級3~5次/d,共治療2周。比較兩組患者治療前后的皮疹分級及改善情況、瘙癢分級及改善情況、生活質(zhì)量指標(biāo)調(diào)查表(DLQI)評分,以及不良反應(yīng)發(fā)生情況。結(jié)果:治療前,兩組患者的皮疹和瘙癢分級情況,以及DLQI評分比較,差異均無統(tǒng)計學(xué)意義(P0.05)。治療后,試驗組患者的皮疹和瘙癢分級情況較本組治療前及對照組均顯著好轉(zhuǎn),差異有統(tǒng)計學(xué)意義(P0.05);試驗組患者的皮疹治療總有效率(67.50%)、瘙癢治療總有效率(70.00%)均顯著高于對照組(分別為20.00%、15.00%),差異均有統(tǒng)計學(xué)意義(P0.05)。試驗組患者的DLQI評分顯著低于本組治療前及對照組,差異均有統(tǒng)計學(xué)意義(P0.05);對照組患者治療前后的DLQI評分比較,差異無統(tǒng)計學(xué)意義(P0.05)。試驗組患者未見明顯不良反應(yīng)發(fā)生。結(jié)論:消疹止癢噴劑能有效緩解EGFRI相關(guān)性皮疹癥狀,減輕瘙癢感,提高患者生活質(zhì)量。
[Abstract]:Objective: to observe the clinical efficacy and safety of Xiaorash antipruritic spray in the treatment of epidermal growth factor receptor inhibitor (EGFRI) associated rash. Methods: from May 2015 to May 2016, 60 cases of malignant tumor diagnosed in our department of oncology were divided into experimental group (n = 40) and control group (n = 20). The patients in the control group did not take any drugs to treat the rash, and the patients in the trial group were treated with antipruritic spray. The treatment frequency was determined by the physician to be 1 / 2 / d / 2 / d / 3 / 3 / 3 / d, 5 times / d for 2 weeks. The grade and improvement of rash, the classification and improvement of pruritus, the (DLQI) score of quality of life questionnaire, and the occurrence of adverse reactions were compared between the two groups before and after treatment. Results: before treatment, there was no significant difference in rash and pruritus grading and DLQI score between the two groups (P0.05). After treatment, the rashes and itching grading of the patients in the experimental group were significantly improved compared with those before treatment and the control group, the difference was statistically significant (P0.05). The total effective rate of skin rash treatment (67.50%) and the total effective rate of pruritus treatment (70.00%) in the trial group were significantly higher than those in the control group (20.00% 15.00%), the difference was statistically significant (P0.05). The DLQI score of the patients in the trial group was significantly lower than that before the treatment and the control group, the difference was statistically significant (P0.05); the DLQI score of the patients in the control group was not significantly different before and after treatment (P0.05). No significant adverse reactions were observed in the trial group. Conclusion: Xiaorash and itching spray can effectively relieve the symptoms of EGFRI associated rash, relieve pruritus and improve the quality of life of patients.
【作者單位】： 蘇州大學(xué)附屬第一醫(yī)院藥學(xué)部;蘇州大學(xué)附屬第一醫(yī)院腫瘤科;
【基金】：江蘇省中醫(yī)藥科技項目(No.YB2015175) 蘇州市科技發(fā)展計劃項目(No.SYSD2014144)
【分類號】：R758.25

【相似文獻(xiàn)】

相關(guān)期刊論文 前1條

1 陸富永;明海霞;尹仲;劉懿;馬蘭;周寧;李艷蕓;;瑞美科皮膚粘膜抗菌護(hù)理噴劑對尖銳濕疣電灼術(shù)后創(chuàng)面的影響[J];中國現(xiàn)代醫(yī)藥雜志;2011年12期

，

本文編號：2387132